Very Low Density Lipoprotein (VLDL)

For Research Use Only. Not for use in diagnostic procedures.

Liquid

At -20 degree C

Small volumes of VLDL protein vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Custom preparations, technical support, bulk quantities and aliquoting available.

Procedure: Ultracentrifugation performed to isolate Human Very Low Density lipoprotein (VLDL). Very Low Density Lipoprotein levels have been correlated with accelerated rates of atherosclerosis, and are elevated in a number of diseases and metabolic states. Human VLDL Inhibits DNA synthesis in lymphocytes activated by the nonspecific mitogen concanavalin A (Con A). Human VLDL are the next step down from chylomicrons in terms of size and lipid content. It transports endogenous triglycerides, phospholipids, cholesterol and cholesteryl esters. This functions as the body's internal transport mechanism for lipids.

VLDL is defined as the lipoprotein fraction with the density range of 0.93 to 1.006 g/mL. It is spherical particle and in normal individuals ranges 30 to 80 nm in diameter. The molecular weight is 10 to 8 107. Compare with LDL particles, VLDL particles are heterogeneous in size and composition. VLDL particles can be separated in Sf 20-60 and Sf60-400. VLDL consists of protein 10%, phospholipid 19%, free cholesterol 7%, cholesterol ester 10% and triglycerides 56%. Apolipoprotein contribution% apoB 37 apoC 50 apoE 13 Apo B-48 is the sole constituent apolipoprotein on VLDL. It is presumed that the cholesteryl esters and triglycerides form the hydrophobic core, which is surrounded by a surface coat of apolipoprotein B, free cholesterol and polar phospholipid components oriented toward the aqueous medium.

Proteins; Antigens; Standards/controls; Native Proteins; Very Low Density Lipoprotein (vldl)

93,383 Da

very low density lipoprotein receptor

very low-density lipoprotein receptor; VLDL-R; VLDL receptor

Very low-density lipoprotein receptor

VLDL receptor; VLDL-R??[Similar Products]

VLDLR_HUMAN

The low density lipoprotein receptor (LDLR) gene family consists of cell surface proteins involved in receptor-mediated endocytosis of specific ligands. This gene encodes a lipoprotein receptor that is a member of the LDLR family and plays important roles in VLDL-triglyceride metabolism and the reelin signaling pathway. Mutations in this gene cause VLDLR-associated cerebellar hypoplasia. Alternative splicing generates multiple transcript variants encoding distinct isoforms for this gene. [provided by RefSeq, Aug 2009]

VLDLR: Binds VLDL and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits. Binding to Reelin induces tyrosine phosphorylation of Dab1 and modulation of Tau phosphorylation. Defects in VLDLR are the cause of cerebellar ataxia mental retardation and dysequilibrium syndrome type 1 (CMARQ1); also known as dysequilibrium syndrome (DES) or non- progressive cerebellar disorder with mental retardation. CMARQ1 is a congenital, non-progressive cerebellar ataxia associated with disturbed equilibrium, delayed ambulation, mental retardation and cerebellar hypoplasia. Additional features include short stature, strabismus, pes planus and, rarely, seizures. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: Membrane protein, integral; Receptor, misc.

Chromosomal Location of Human Ortholog: 9p24

Cellular Component: membrane; integral to membrane; plasma membrane; coated pit; receptor complex

Molecular Function: very-low-density lipoprotein receptor activity; low-density lipoprotein receptor activity; very-low-density lipoprotein binding; protein binding; apolipoprotein binding; calcium ion binding; glycoprotein binding; calcium-dependent protein binding

Biological Process: cholesterol metabolic process; nervous system development; receptor-mediated endocytosis; positive regulation of protein kinase activity; ventral spinal cord development; negative regulation of transcription from RNA polymerase II promoter; lipid transport; signal transduction; memory

Disease: Cerebellar Ataxia, Mental Retardation, And Dysequilibrium Syndrome 1

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.